Increasing evidence demonstrates that blocking the interaction between CD47 and SIRPα can enhance cancer cell clearance by macrophages, which is particularly relevant in SCLC, where TAMs are the dominant cell type in the TME [13,76]. Here, SIRPA is linked to cancer.